Literature DB >> 12297849

Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies.

Alberto Larghi1, Massimo Zuin, Andrea Crosignani, Maria Lisa Ribero, Cristina Pipia, Pier Maria Battezzati, Giorgio Binelli, Francesco Donato, Alessandro Remo Zanetti, Mauro Podda, Alessandro Tagger.   

Abstract

We identified 15 patients with acute hepatitis C (AHC) among 29 healthy volunteers participating in 2 consecutive pharmacokinetics studies. Molecular techniques were used to determine the relatedness of viral strains, whereas clinical and virologic follow-up was started to establish the course and outcome of the acute infection. After presentation, serum liver enzymes and HCV RNA were monitored weekly for 4 months, then monthly for at least 12 months. Liver biopsy was performed 6 to 12 months after AHC diagnosis. Phylogenetic analysis of coding regions for the envelope glycoproteins E1 and E2 was performed. At presentation, all 15 patients tested HCV RNA-positive and had HCV genotype 2c. Phylogenetic analysis indicated a common source of infection. Fourteen patients agreed to be followed prospectively. Infection resolved spontaneously in 8 patients, HCV RNA becoming undetectable by 4 to 5 months after the presumed time of infection in 5 of them and by 8, 13, and 24 months in the remaining 3. Six patients developed chronic infection. Liver biopsies performed in 9 subjects who were HCV RNA-positive 6 months after AHC diagnosis revealed that the prevalent histologic finding was lobular inflammation. In conclusion, our homogeneous cohort showed a wide spectrum of clinical, virologic and histologic features, and, more importantly, short-term outcome differed noticeably despite the common source of infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297849     DOI: 10.1053/jhep.2002.36129

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

Review 1.  Acute hepatitis C virus infection: a neglected disease?

Authors:  W L Irving
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

2.  Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France.

Authors:  C Brouard; P Pradat; E Delarocque-Astagneau; C Silvain
Journal:  Epidemiol Infect       Date:  2007-08-16       Impact factor: 2.451

Review 3.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis.

Authors:  K E Corey; J Mendez-Navarro; E C Gorospe; H Zheng; R T Chung
Journal:  J Viral Hepat       Date:  2009-08-06       Impact factor: 3.728

6.  A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME).

Authors:  Leslie H Tobler; Shrein H Bahrami; Zhanna Kaidarova; Lubov Pitina; Valarie K Winkelman; Sandra K Vanderpool; Anne M Guiltinan; Stewart Cooper; Michael P Busch; Edward L Murphy
Journal:  Transfusion       Date:  2010-03-25       Impact factor: 3.157

Review 7.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

8.  Outcomes and treatment of acute hepatitis C virus infection in a United States population.

Authors:  Kathleen E Corey; Andrew S Ross; Alysse Wurcel; Julian Schulze Zur Wiesch; Arthur Y Kim; Georg M Lauer; Raymond T Chung
Journal:  Clin Gastroenterol Hepatol       Date:  2006-08-22       Impact factor: 11.382

9.  Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index.

Authors:  S Klimashevskaya; A Obriadina; T Ulanova; G Bochkova; A Burkov; A Araujo; Susan L Stramer; Leslie H Tobler; Michael P Busch; Howard A Fields
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

10.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.